TGFbeta Inhibitor LY3200882

**Semantic type:** Pharmacologic Substance

**Definition:** An orally bioavailable agent that targets transforming growth factor-beta (TGFb), with potential antineoplastic activity. Upon administration, LY3200882 specifically targets and binds to TGFb, which prevents both the binding of TGFb to its receptor TGFbR and TGFb-mediated signal transduction. This may lead to a reduction in TGFb-dependent proliferation of cancer cells. The TGFb signaling pathway is often deregulated in tumors, and plays a key role in the regulation of cell growth, differentiation, apoptosis, motility, invasion, angiogenesis, and various immune responses.

**Synonyms:** - LY 3200882 - LY-3200882 - LY3200882 - TGFb Inhibitor LY 3200882